IP69-15: From Trial to Practice: No Survival Benefit from Adjuvant Mitotane in Low-Risk Adrenocortical Carcinoma, Insights from a Nationwide Cohort
Sunday, May 17, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)
146B
Abstract
Log in
See all the content and easy-to-use features by logging in or registering!